Published in Br J Clin Pharmacol on July 01, 2005
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol (2007) 1.52
Response to bosentan in children with pulmonary hypertension. Heart (2005) 1.26
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J (2008) 1.10
Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag (2007) 1.09
Pulmonary arterial hypertension associated with systemic sclerosis. Expert Rev Respir Med (2011) 0.95
Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart (2005) 0.95
Sildenafil for the treatment of pulmonary hypertension in pediatric patients. Pediatr Cardiol (2009) 0.92
Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. J Cardiovasc Transl Res (2010) 0.85
Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Curr Opin Rheumatol (2009) 0.80
2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2014) 0.77
The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vasc Health Risk Manag (2010) 0.77
Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects. Br J Clin Pharmacol (2014) 0.77
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension. Ann Thorac Med (2014) 0.77
Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. Vasc Health Risk Manag (2008) 0.77
Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors--assembling the clues. Br J Clin Pharmacol (2009) 0.75
The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol (2010) 0.75
AMBITION: An important piece in the therapeutic puzzle of pulmonary arterial hypertension. Glob Cardiol Sci Pract (2015) 0.75
Safety and tolerability of bosentan in the management of pulmonary arterial hypertension. Drug Des Devel Ther (2009) 0.75
Acute haemodynamic response in relation to plasma vardenafil concentrations in patients with pulmonary hypertension. Br J Clin Pharmacol (2012) 0.75
Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. Future Cardiol (2013) 0.75
Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. Br J Clin Pharmacol (2015) 0.75
Macitentan in pulmonary arterial hypertension: The SERAPHIN trial. Glob Cardiol Sci Pract (2014) 0.75
High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. Eur J Clin Pharmacol (2012) 0.75
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Primary pulmonary hypertension. Lancet (2003) 3.08
Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med (2003) 2.90
Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem (1999) 2.23
Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol (2002) 2.16
Diltiazem-mediated inhibition of sildenafil metabolism may promote nitrate-induced hypotension. Aust N Z J Med (2000) 2.11
Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica (1999) 2.03
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet (2004) 1.66
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation (2003) 1.57
Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol (2001) 1.45
Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol (2002) 1.20
Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol (2000) 1.18
In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos (2000) 1.18
Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J (2004) 1.13
The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol (2002) 0.99
A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J (2002) 0.92
Simultaneous assay of sildenafil and desmethylsildenafil in human plasma using liquid chromatography-tandem mass spectrometry on silica column with aqueous-organic mobile phase. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.87
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med (2013) 5.22
ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J (2011) 5.11
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation (2013) 3.90
Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med (2008) 3.67
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85
Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.57
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation (2012) 2.54
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med (2005) 2.49
Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J (2006) 2.49
Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol (2011) 2.39
Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor. JAMA (2002) 2.23
Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation (2008) 2.18
Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. Cancer Causes Control (2006) 2.17
Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med (2012) 2.00
Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab (2010) 1.85
The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica (2012) 1.72
Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework. Regul Toxicol Pharmacol (2011) 1.67
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood (2011) 1.64
End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 1.63
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation (2005) 1.62
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation (2003) 1.57
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med (2005) 1.56
Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med (2008) 1.52
emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J (2013) 1.52
Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol (2011) 1.48
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol (2012) 1.48
Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin Sci (Lond) (2002) 1.46
Patient descriptions of breathlessness in heart failure. Int J Cardiol (2005) 1.42
Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation (2008) 1.39
Effect of altitude on the heart and the lungs. Circulation (2007) 1.38
Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol (2003) 1.23
Systems toxicology: from basic research to risk assessment. Chem Res Toxicol (2014) 1.23
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab (2007) 1.22
Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos (2003) 1.20
The Key Events Dose-Response Framework: a cross-disciplinary mode-of-action based approach to examining dose-response and thresholds. Crit Rev Food Sci Nutr (2009) 1.18
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat (2011) 1.18
Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation (2010) 1.16
Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med (2010) 1.15
Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 1.12
Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 1.11
Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart (2011) 1.09
A 21st century roadmap for human health risk assessment. Crit Rev Toxicol (2014) 1.07
Cruciferous vegetable consumption alters the metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in humans. Carcinogenesis (2004) 1.04
A qualitative study of chronic heart failure patients' understanding of their symptoms and drug therapy. Eur J Heart Fail (2002) 1.02
Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med (2006) 1.01
Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res (2012) 1.01
Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol (2007) 1.00
cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol (2004) 1.00
Measuring the heart in pulmonary arterial hypertension (PAH): implications for trial study size. J Magn Reson Imaging (2010) 1.00
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation (2003) 1.00
Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: consequences for risk from exposure to diazinon. Pharmacogenet Genomics (2005) 0.99
Testicular dysgenesis syndrome and the estrogen hypothesis: a quantitative meta-analysis. Environ Health Perspect (2008) 0.99
Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J (2012) 0.98
The association of clinical outcome with right atrial and ventricular remodelling in patients with pulmonary arterial hypertension: study with real-time three-dimensional echocardiography. Eur Heart J Cardiovasc Imaging (2012) 0.97
Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther (2008) 0.97
CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet Genomics (2005) 0.97
Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci (2005) 0.96
Expression of P450 enzymes in rat whole skin and cultured epidermal keratinocytes. Biochem Biophys Res Commun (2002) 0.95
Risk assessment in the 21st century: roadmap and matrix. Crit Rev Toxicol (2014) 0.95
Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse (2011) 0.95
Identification of estrogen-responsive proteins in MCF-7 human breast cancer cells using label-free quantitative proteomics. Proteomics (2008) 0.95
Nasal epithelium potential difference at high altitude (4,559 m): evidence for secretion. Am J Respir Crit Care Med (2003) 0.95
Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol (2006) 0.95
A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One (2012) 0.94
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 0.93
Survey of specialist palliative care and heart failure: September 2004. Palliat Med (2006) 0.93
Understanding late gadolinium enhancement in pulmonary hypertension. Circ Cardiovasc Imaging (2010) 0.92
Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. Proteomics (2006) 0.91
Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol (2005) 0.91
Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype. Am J Respir Crit Care Med (2002) 0.91
Influence of operating parameters on the biodegradation of steroid estrogens and nonylphenolic compounds during biological wastewater treatment processes. Environ Sci Technol (2009) 0.91
Cardiovascular magnetic resonance in pulmonary hypertension. J Cardiovasc Magn Reson (2012) 0.90
Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos (2003) 0.90
Expression of CYP3A4 in human breast tumour and non-tumour tissues. Cancer Lett (2003) 0.89
Elucidation of toxicity pathways in lung epithelial cells induced by silicon dioxide nanoparticles. PLoS One (2013) 0.89
Using mode of action information to improve regulatory decision-making: an ECETOC/ILSI RF/HESI workshop overview. Crit Rev Toxicol (2011) 0.88
Agricultural chemical safety assessment: A multisector approach to the modernization of human safety requirements. Crit Rev Toxicol (2006) 0.88
Differences in ventilatory inefficiency between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest (2011) 0.88
Increased expression of histone proteins during estrogen-mediated cell proliferation. Environ Health Perspect (2009) 0.88
Human health and endocrine disruption: a simple multicriteria framework for the qualitative assessment of end point specific risks in a context of scientific uncertainty. Toxicol Sci (2007) 0.88
Validation of the isovolumetric relaxation time for the estimation of pulmonary systolic arterial blood pressure in chronic pulmonary hypertension. Eur Heart J Cardiovasc Imaging (2012) 0.86
Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. Exp Lung Res (2010) 0.86
Global food supply. Reevaluate pesticides for food security and safety. Science (2013) 0.86
Comparison of 18F-FDG uptake by right ventricular myocardium in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease. Pulm Circ (2012) 0.86
Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension. Pulm Circ (2013) 0.85